Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927968 | 0.93 | CYP3A4 (0.45) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9927978 | 0.93 | CYP3A4 (0.45) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9927996 | 0.93 | CYP3A4 (0.45) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9927972 | 0.93 | CYP3A4 (0.45) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9927983 | 0.93 | CYP3A4 (0.50) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL16298549 | 0.92 | CYP3A4 (0.43) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9928019 | 0.92 | CYP3A4 (0.43) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL23837954 | 0.91 | CYP3A4 (0.43) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL12269731 | 0.91 | CYP3A4 (0.43) | CYP3A4MMP9MMP8MMP14HTT | |
| SCHEMBL9927990 | 0.91 | CYP3A4 (0.43) | CYP3A4MMP9MMP8MMP14HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678343-B1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | NALCO CO (US) | 2021-09-22 | — | — | EP | disclosed |
| US-9944534-B2 | Reducing aluminosilicate scale in the Bayer process | ECOLAB USA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944534-B2 | Reducing aluminosilicate scale in the Bayer process | ECOLAB USA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | NALCO COMPANY (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | NALCO COMPANY (US) | 2017-02-23 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2013126683-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | NALCO COMPANY (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | DSP, SOST, SORD | CYP3A4 4175/4885MMP9 2567/4885MMP8 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.